Bristol Meyers can’t convince circuit to overturn $1.2bn ruling

18-01-2022

Alex Baldwin

Bristol Meyers can’t convince circuit to overturn $1.2bn ruling

nitpicker / Shutterstock.com

The US Court of Appeals for the Federal Circuit has turned down a Bristol Myers Squibb subsidiary’s appeal to overturn a controversial $1.2 billion patent verdict loss against Kite Pharma.


Kite Pharmaceuticals, Juno Therapeutics, Bristol Meyers Squibb, Gilead Sciences

LSIPR